Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX97 in Advanced/Metastatic Solid Tumors
NCT07480681Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of HLX97 in solid tumor, breast cancer, prostate cancer (PCa) and 1 more (2 arms), sponsored by Henlius. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HLX97
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07480681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480681.